



Company News

Renopharm has received a notice of allowance of its US patent application covering its lead compound **Pet-8**, for treating cardiovascular disorders and related medical conditions.

The biotechnology company Renopharm Ltd. today announced it has received an notice of allowance for its US Patent Application **No. 20060183718**, THIAZOLE-BASED NITRIC OXIDE DONORS HAVING ARYL SUBSTITUENT(S) AND USES THEROF.

About Pet-8:

A derivative of the active side of Vitamin B1, was successfully synthesized, analyzed and fully characterized. **Pet-8**, a nitric oxide donor, do not induce tolerance after repeated administration, thus its application for hypertension provide the most ever discovered semi-natural method for treating high blood pressure.

Preclinical results fully supported the rationale for using Renopharm's nitric oxide-donating technology to develop the next generation of antihypertensive drugs.

Pet-8 was dosed at a very high level (600mg/Kg) without finding any toxicity (Approved by the NIH, USA).

Contact Information

Dr. Peter Assaf, CEO

Renopharm Ltd.

Nazareth 16000

Israel

E-mail: peter@renopharm.com

Tel.: +972.4.6565.211

Fax:+972.4.6564.129

www.renopharm.com